James Crowe Jr.

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus. Read More

Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM). Read More

Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. Read More

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

Chancellor Daniel Diermeier outlined a bold path forward for Vanderbilt University, challenging the university community to “set our aspirations higher” during his Fall Faculty Assembly address. Read More

A monoclonal antibody cocktail against the COVID-19 virus discovered at VUMC is the first non-vaccine modified to demonstrate the prevention of COVID-19 in a clinical trial of more than 5,000 participants. The antibody treatment could afford up to 12 months of protection from COVID-19, and preliminary laboratory findings also suggest that it can neutralize the delta variant. Read More

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The Center for Technology Transfer and Commercialization continued to play a pivotal role in translating the research findings of Vanderbilt faculty into products and companies in 2020 that have the potential to transform many aspects of life, from disease prevention to quality of life-enhancing products. Read More

Dr. James E. Crowe Jr., a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read More

Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.  Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read More

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern. Read More

To keep pace with Vanderbilt researchers developing COVID-19 solutions, the Center for Technology Transfer & Commercialization has facilitated three license agreements, 11 patent applications and 43 material transfer agreements in record time. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More